Article Information
History
- September 1, 2024.
Article Versions
- You are currently viewing Version 1 of this article (September 1, 2024 - 20:24).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Yu Zhang1,2,3,4,†,
- Shuo Cao1,†,
- Nan Niu1,2,3,
- Huilian Shan1,
- Jinqi Xue1,2,3,†,
- Guanglei Chen1,2,3,†,
- Yongqing Xu1,
- Jianqiao Yin1,
- Chao Liu1,2,3,
- Lisha Sun1,2,3,
- Xiaofan Jiang1,2,3,
- Meiyue Tang1,
- Qianshi Xu1,2,
- Mingxuan Jia1,
- Xu Zhang1,
- Zhenyong Zhang1,
- Qingfu Zhang5,
- Jianfei Wang6,
- Ailin Li1,
- Yongliang Yang7 and
- Caigang Liu1,2,3,*
- 1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
- 2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
- 3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
- 4Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
- 5Department of Pathology, the First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China
- 6Jiangsu Hengrui Pharmaceuticals, Shanghai, China
- 7School of Bioengineering, Dalian University of Technology, Dalian, China
- ↵*Corresponding author:
Caigang Liu, MD, PhD Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China Tel.: 86-18940254967 E-mail: liucg{at}sj-hospital.org
↵† Shuo Cao, Yu Zhang, Jinqi Xue and Guanglei Chen contributed equally to this work.
Posted September 01, 2024.
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
